nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—STK33—cerebellum—intracranial aneurysm	0.00234	0.00507	CbGeAlD
Bosutinib—PLK2—midbrain—intracranial aneurysm	0.00231	0.005	CbGeAlD
Bosutinib—SIK3—midbrain—intracranial aneurysm	0.00229	0.00497	CbGeAlD
Bosutinib—EPHA5—medulla oblongata—intracranial aneurysm	0.00228	0.00494	CbGeAlD
Bosutinib—ALK—medulla oblongata—intracranial aneurysm	0.00228	0.00494	CbGeAlD
Bosutinib—FER—medulla oblongata—intracranial aneurysm	0.00228	0.00494	CbGeAlD
Bosutinib—PKMYT1—cerebellum—intracranial aneurysm	0.00228	0.00494	CbGeAlD
Bosutinib—DSTYK—cerebellum—intracranial aneurysm	0.00223	0.00482	CbGeAlD
Bosutinib—CLK3—cerebellum—intracranial aneurysm	0.00223	0.00482	CbGeAlD
Bosutinib—BTK—medulla oblongata—intracranial aneurysm	0.00223	0.00482	CbGeAlD
Bosutinib—MAST1—brain—intracranial aneurysm	0.00219	0.00475	CbGeAlD
Bosutinib—CASK—cerebellum—intracranial aneurysm	0.00218	0.00471	CbGeAlD
Bosutinib—PHKG1—cerebellum—intracranial aneurysm	0.00218	0.00471	CbGeAlD
Bosutinib—MAP4K2—medulla oblongata—intracranial aneurysm	0.00216	0.00468	CbGeAlD
Bosutinib—EIF2AK1—cerebellum—intracranial aneurysm	0.00215	0.00466	CbGeAlD
Bosutinib—ERBB4—medulla oblongata—intracranial aneurysm	0.00213	0.00462	CbGeAlD
Bosutinib—EPHA8—cerebellum—intracranial aneurysm	0.00209	0.00452	CbGeAlD
Bosutinib—FER—midbrain—intracranial aneurysm	0.00209	0.00452	CbGeAlD
Bosutinib—ALK—midbrain—intracranial aneurysm	0.00209	0.00452	CbGeAlD
Bosutinib—EPHA5—midbrain—intracranial aneurysm	0.00209	0.00452	CbGeAlD
Bosutinib—FYN—brainstem—intracranial aneurysm	0.00208	0.00451	CbGeAlD
Bosutinib—TNIK—cerebellum—intracranial aneurysm	0.00205	0.00443	CbGeAlD
Bosutinib—BMPR2—medulla oblongata—intracranial aneurysm	0.00205	0.00443	CbGeAlD
Bosutinib—STK36—medulla oblongata—intracranial aneurysm	0.00203	0.00439	CbGeAlD
Bosutinib—STK26—cerebellum—intracranial aneurysm	0.00201	0.00435	CbGeAlD
Bosutinib—MAP4K2—midbrain—intracranial aneurysm	0.00198	0.00428	CbGeAlD
Bosutinib—MAP4K4—medulla oblongata—intracranial aneurysm	0.00197	0.00426	CbGeAlD
Bosutinib—BCR—medulla oblongata—intracranial aneurysm	0.00196	0.00423	CbGeAlD
Bosutinib—TLK1—brain—intracranial aneurysm	0.00196	0.00423	CbGeAlD
Bosutinib—ERBB4—midbrain—intracranial aneurysm	0.00195	0.00422	CbGeAlD
Bosutinib—MAP3K12—medulla oblongata—intracranial aneurysm	0.00194	0.0042	CbGeAlD
Bosutinib—PRKCQ—brain—intracranial aneurysm	0.00193	0.00417	CbGeAlD
Bosutinib—WEE1—cerebellum—intracranial aneurysm	0.00193	0.00417	CbGeAlD
Bosutinib—DMPK—cerebellum—intracranial aneurysm	0.00193	0.00417	CbGeAlD
Bosutinib—SIK2—brain—intracranial aneurysm	0.0019	0.00412	CbGeAlD
Bosutinib—STK33—brain—intracranial aneurysm	0.0019	0.00412	CbGeAlD
Bosutinib—CSK—medulla oblongata—intracranial aneurysm	0.00189	0.00409	CbGeAlD
Bosutinib—CSNK1A1—medulla oblongata—intracranial aneurysm	0.00188	0.00406	CbGeAlD
Bosutinib—BMPR2—midbrain—intracranial aneurysm	0.00187	0.00405	CbGeAlD
Bosutinib—HCK—medulla oblongata—intracranial aneurysm	0.00187	0.00404	CbGeAlD
Bosutinib—CLK1—medulla oblongata—intracranial aneurysm	0.00187	0.00404	CbGeAlD
Bosutinib—TAOK3—brainstem—intracranial aneurysm	0.00186	0.00401	CbGeAlD
Bosutinib—PKMYT1—brain—intracranial aneurysm	0.00185	0.00401	CbGeAlD
Bosutinib—STK25—cerebellum—intracranial aneurysm	0.00184	0.00398	CbGeAlD
Bosutinib—CAMK2G—medulla oblongata—intracranial aneurysm	0.00183	0.00396	CbGeAlD
Bosutinib—LRRK2—medulla oblongata—intracranial aneurysm	0.00182	0.00393	CbGeAlD
Bosutinib—DSTYK—brain—intracranial aneurysm	0.00181	0.00392	CbGeAlD
Bosutinib—CLK3—brain—intracranial aneurysm	0.00181	0.00392	CbGeAlD
Bosutinib—MAP4K4—midbrain—intracranial aneurysm	0.0018	0.0039	CbGeAlD
Bosutinib—HIPK4—brain—intracranial aneurysm	0.00179	0.00387	CbGeAlD
Bosutinib—BCR—midbrain—intracranial aneurysm	0.00179	0.00387	CbGeAlD
Bosutinib—PLK2—cerebellum—intracranial aneurysm	0.00179	0.00387	CbGeAlD
Bosutinib—SIK3—cerebellum—intracranial aneurysm	0.00178	0.00384	CbGeAlD
Bosutinib—MAP3K12—midbrain—intracranial aneurysm	0.00178	0.00384	CbGeAlD
Bosutinib—PHKG1—brain—intracranial aneurysm	0.00177	0.00383	CbGeAlD
Bosutinib—CASK—brain—intracranial aneurysm	0.00177	0.00383	CbGeAlD
Bosutinib—EPHB2—brain—intracranial aneurysm	0.00177	0.00383	CbGeAlD
Bosutinib—EIF2AK1—brain—intracranial aneurysm	0.00175	0.00379	CbGeAlD
Bosutinib—CSNK1E—medulla oblongata—intracranial aneurysm	0.00174	0.00377	CbGeAlD
Bosutinib—STK35—midbrain—intracranial aneurysm	0.00174	0.00376	CbGeAlD
Bosutinib—SRMS—brain—intracranial aneurysm	0.00173	0.00375	CbGeAlD
Bosutinib—CSK—midbrain—intracranial aneurysm	0.00173	0.00374	CbGeAlD
Bosutinib—CSNK1A1—midbrain—intracranial aneurysm	0.00172	0.00371	CbGeAlD
Bosutinib—SIK1—medulla oblongata—intracranial aneurysm	0.00171	0.00371	CbGeAlD
Bosutinib—IRAK4—medulla oblongata—intracranial aneurysm	0.00171	0.00371	CbGeAlD
Bosutinib—STK4—cerebellum—intracranial aneurysm	0.00171	0.0037	CbGeAlD
Bosutinib—HCK—midbrain—intracranial aneurysm	0.00171	0.00369	CbGeAlD
Bosutinib—CLK1—midbrain—intracranial aneurysm	0.00171	0.00369	CbGeAlD
Bosutinib—EPHA4—medulla oblongata—intracranial aneurysm	0.0017	0.00367	CbGeAlD
Bosutinib—VRK2—brain—intracranial aneurysm	0.0017	0.00367	CbGeAlD
Bosutinib—EPHA8—brain—intracranial aneurysm	0.0017	0.00367	CbGeAlD
Bosutinib—FES—brain—intracranial aneurysm	0.0017	0.00367	CbGeAlD
Bosutinib—CAMK1D—cerebellum—intracranial aneurysm	0.00169	0.00365	CbGeAlD
Bosutinib—MAP2K2—medulla oblongata—intracranial aneurysm	0.00168	0.00362	CbGeAlD
Bosutinib—ULK3—medulla oblongata—intracranial aneurysm	0.00168	0.00362	CbGeAlD
Bosutinib—BMP2K—midbrain—intracranial aneurysm	0.00167	0.00362	CbGeAlD
Bosutinib—CAMK2G—midbrain—intracranial aneurysm	0.00167	0.00362	CbGeAlD
Bosutinib—STK24—cerebellum—intracranial aneurysm	0.00167	0.00361	CbGeAlD
Bosutinib—TNIK—brain—intracranial aneurysm	0.00166	0.0036	CbGeAlD
Bosutinib—SYK—brain—intracranial aneurysm	0.00166	0.0036	CbGeAlD
Bosutinib—MAP2K5—brainstem—intracranial aneurysm	0.00166	0.0036	CbGeAlD
Bosutinib—LRRK2—midbrain—intracranial aneurysm	0.00166	0.00359	CbGeAlD
Bosutinib—MAP3K7—medulla oblongata—intracranial aneurysm	0.00165	0.00357	CbGeAlD
Bosutinib—CDK2—brain—intracranial aneurysm	0.00165	0.00356	CbGeAlD
Bosutinib—STK26—brain—intracranial aneurysm	0.00163	0.00353	CbGeAlD
Bosutinib—TBK1—medulla oblongata—intracranial aneurysm	0.00163	0.00352	CbGeAlD
Bosutinib—FER—cerebellum—intracranial aneurysm	0.00162	0.00349	CbGeAlD
Bosutinib—TYRO3—cerebellum—intracranial aneurysm	0.00162	0.00349	CbGeAlD
Bosutinib—EPHA5—cerebellum—intracranial aneurysm	0.00162	0.00349	CbGeAlD
Bosutinib—CSNK1E—midbrain—intracranial aneurysm	0.00159	0.00344	CbGeAlD
Bosutinib—CHEK2—brain—intracranial aneurysm	0.00158	0.00341	CbGeAlD
Bosutinib—RPS6KB1—medulla oblongata—intracranial aneurysm	0.00157	0.00339	CbGeAlD
Bosutinib—DMPK—brain—intracranial aneurysm	0.00156	0.00338	CbGeAlD
Bosutinib—WEE1—brain—intracranial aneurysm	0.00156	0.00338	CbGeAlD
Bosutinib—TNK2—cerebellum—intracranial aneurysm	0.00155	0.00336	CbGeAlD
Bosutinib—AXL—medulla oblongata—intracranial aneurysm	0.00155	0.00336	CbGeAlD
Bosutinib—ERBB3—midbrain—intracranial aneurysm	0.00153	0.00332	CbGeAlD
Bosutinib—MAP2K2—midbrain—intracranial aneurysm	0.00153	0.00331	CbGeAlD
Bosutinib—ULK3—midbrain—intracranial aneurysm	0.00153	0.00331	CbGeAlD
Bosutinib—MAP4K2—cerebellum—intracranial aneurysm	0.00153	0.00331	CbGeAlD
Bosutinib—ERBB4—cerebellum—intracranial aneurysm	0.00151	0.00327	CbGeAlD
Bosutinib—STK3—cerebellum—intracranial aneurysm	0.00151	0.00327	CbGeAlD
Bosutinib—MAP3K7—midbrain—intracranial aneurysm	0.00151	0.00326	CbGeAlD
Bosutinib—SLK—medulla oblongata—intracranial aneurysm	0.00149	0.00323	CbGeAlD
Bosutinib—STK25—brain—intracranial aneurysm	0.00149	0.00323	CbGeAlD
Bosutinib—PTK2—midbrain—intracranial aneurysm	0.00149	0.00322	CbGeAlD
Bosutinib—TBK1—midbrain—intracranial aneurysm	0.00149	0.00322	CbGeAlD
Bosutinib—EPHB4—medulla oblongata—intracranial aneurysm	0.00148	0.00321	CbGeAlD
Bosutinib—EPHA3—brain—intracranial aneurysm	0.00148	0.00321	CbGeAlD
Bosutinib—IRAK1—midbrain—intracranial aneurysm	0.00146	0.00316	CbGeAlD
Bosutinib—FYN—medulla oblongata—intracranial aneurysm	0.00145	0.00314	CbGeAlD
Bosutinib—PLK2—brain—intracranial aneurysm	0.00145	0.00314	CbGeAlD
Bosutinib—BMPR2—cerebellum—intracranial aneurysm	0.00145	0.00313	CbGeAlD
Bosutinib—SIK3—brain—intracranial aneurysm	0.00144	0.00312	CbGeAlD
Bosutinib—STK36—cerebellum—intracranial aneurysm	0.00144	0.00311	CbGeAlD
Bosutinib—EPHB3—cerebellum—intracranial aneurysm	0.00144	0.00311	CbGeAlD
Bosutinib—RPS6KB1—midbrain—intracranial aneurysm	0.00143	0.0031	CbGeAlD
Bosutinib—MERTK—cerebellum—intracranial aneurysm	0.00142	0.00307	CbGeAlD
Bosutinib—MAP4K5—medulla oblongata—intracranial aneurysm	0.00142	0.00307	CbGeAlD
Bosutinib—MAP3K3—medulla oblongata—intracranial aneurysm	0.00142	0.00307	CbGeAlD
Bosutinib—AXL—midbrain—intracranial aneurysm	0.00142	0.00307	CbGeAlD
Bosutinib—MAP4K4—cerebellum—intracranial aneurysm	0.00139	0.00301	CbGeAlD
Bosutinib—STK4—brain—intracranial aneurysm	0.00139	0.003	CbGeAlD
Bosutinib—NUAK2—cerebellum—intracranial aneurysm	0.00138	0.00299	CbGeAlD
Bosutinib—BCR—cerebellum—intracranial aneurysm	0.00138	0.00299	CbGeAlD
Bosutinib—MAP3K12—cerebellum—intracranial aneurysm	0.00137	0.00297	CbGeAlD
Bosutinib—CAMK1D—brain—intracranial aneurysm	0.00137	0.00297	CbGeAlD
Bosutinib—SLK—midbrain—intracranial aneurysm	0.00136	0.00295	CbGeAlD
Bosutinib—STK24—brain—intracranial aneurysm	0.00136	0.00293	CbGeAlD
Bosutinib—EPHB4—midbrain—intracranial aneurysm	0.00135	0.00293	CbGeAlD
Bosutinib—MAP2K1—cerebellum—intracranial aneurysm	0.00135	0.00291	CbGeAlD
Bosutinib—STK35—cerebellum—intracranial aneurysm	0.00135	0.00291	CbGeAlD
Bosutinib—CSK—cerebellum—intracranial aneurysm	0.00134	0.00289	CbGeAlD
Bosutinib—CSNK1A1—cerebellum—intracranial aneurysm	0.00133	0.00287	CbGeAlD
Bosutinib—FYN—midbrain—intracranial aneurysm	0.00133	0.00287	CbGeAlD
Bosutinib—CLK1—cerebellum—intracranial aneurysm	0.00132	0.00285	CbGeAlD
Bosutinib—FER—brain—intracranial aneurysm	0.00131	0.00284	CbGeAlD
Bosutinib—TYRO3—brain—intracranial aneurysm	0.00131	0.00284	CbGeAlD
Bosutinib—ALK—brain—intracranial aneurysm	0.00131	0.00284	CbGeAlD
Bosutinib—EPHA5—brain—intracranial aneurysm	0.00131	0.00284	CbGeAlD
Bosutinib—ABL2—cerebellum—intracranial aneurysm	0.00131	0.00284	CbGeAlD
Bosutinib—YES1—medulla oblongata—intracranial aneurysm	0.00131	0.00284	CbGeAlD
Bosutinib—LYN—brain—intracranial aneurysm	0.00131	0.00282	CbGeAlD
Bosutinib—MAP4K5—midbrain—intracranial aneurysm	0.0013	0.00281	CbGeAlD
Bosutinib—MAP3K3—midbrain—intracranial aneurysm	0.0013	0.00281	CbGeAlD
Bosutinib—CAMK2G—cerebellum—intracranial aneurysm	0.0013	0.0028	CbGeAlD
Bosutinib—BMP2K—cerebellum—intracranial aneurysm	0.0013	0.0028	CbGeAlD
Bosutinib—TAOK3—medulla oblongata—intracranial aneurysm	0.00129	0.0028	CbGeAlD
Bosutinib—MAP4K1—brain—intracranial aneurysm	0.00129	0.00278	CbGeAlD
Bosutinib—MAP3K19—brain—intracranial aneurysm	0.00129	0.00278	CbGeAlD
Bosutinib—LRRK2—cerebellum—intracranial aneurysm	0.00128	0.00278	CbGeAlD
Bosutinib—ABL1—brainstem—intracranial aneurysm	0.00128	0.00278	CbGeAlD
Bosutinib—EGFR—cerebellum—intracranial aneurysm	0.00128	0.00277	CbGeAlD
Bosutinib—BTK—brain—intracranial aneurysm	0.00128	0.00277	CbGeAlD
Bosutinib—TNK2—brain—intracranial aneurysm	0.00126	0.00273	CbGeAlD
Bosutinib—PTK2B—cerebellum—intracranial aneurysm	0.00125	0.00271	CbGeAlD
Bosutinib—MAP4K2—brain—intracranial aneurysm	0.00124	0.00269	CbGeAlD
Bosutinib—CSNK1E—cerebellum—intracranial aneurysm	0.00123	0.00266	CbGeAlD
Bosutinib—ERBB4—brain—intracranial aneurysm	0.00123	0.00265	CbGeAlD
Bosutinib—STK3—brain—intracranial aneurysm	0.00123	0.00265	CbGeAlD
Bosutinib—IRAK4—cerebellum—intracranial aneurysm	0.00121	0.00262	CbGeAlD
Bosutinib—SIK1—cerebellum—intracranial aneurysm	0.00121	0.00262	CbGeAlD
Bosutinib—ROCK1—brain—intracranial aneurysm	0.00121	0.00262	CbGeAlD
Bosutinib—EPHA4—cerebellum—intracranial aneurysm	0.0012	0.00259	CbGeAlD
Bosutinib—YES1—midbrain—intracranial aneurysm	0.0012	0.00259	CbGeAlD
Bosutinib—ERBB3—cerebellum—intracranial aneurysm	0.00119	0.00257	CbGeAlD
Bosutinib—ULK3—cerebellum—intracranial aneurysm	0.00118	0.00256	CbGeAlD
Bosutinib—MAP2K2—cerebellum—intracranial aneurysm	0.00118	0.00256	CbGeAlD
Bosutinib—TAOK3—midbrain—intracranial aneurysm	0.00118	0.00256	CbGeAlD
Bosutinib—MAP3K2—cerebellum—intracranial aneurysm	0.00118	0.00254	CbGeAlD
Bosutinib—BMPR2—brain—intracranial aneurysm	0.00118	0.00254	CbGeAlD
Bosutinib—STK36—brain—intracranial aneurysm	0.00117	0.00252	CbGeAlD
Bosutinib—EPHB3—brain—intracranial aneurysm	0.00117	0.00252	CbGeAlD
Bosutinib—MAP3K7—cerebellum—intracranial aneurysm	0.00117	0.00252	CbGeAlD
Bosutinib—MAP2K5—medulla oblongata—intracranial aneurysm	0.00116	0.00251	CbGeAlD
Bosutinib—MERTK—brain—intracranial aneurysm	0.00115	0.00249	CbGeAlD
Bosutinib—TBK1—cerebellum—intracranial aneurysm	0.00115	0.00249	CbGeAlD
Bosutinib—PTK2—cerebellum—intracranial aneurysm	0.00115	0.00249	CbGeAlD
Bosutinib—CSF1R—medulla oblongata—intracranial aneurysm	0.00113	0.00245	CbGeAlD
Bosutinib—MAP4K4—brain—intracranial aneurysm	0.00113	0.00245	CbGeAlD
Bosutinib—IRAK1—cerebellum—intracranial aneurysm	0.00113	0.00244	CbGeAlD
Bosutinib—BCR—brain—intracranial aneurysm	0.00112	0.00243	CbGeAlD
Bosutinib—NUAK2—brain—intracranial aneurysm	0.00112	0.00243	CbGeAlD
Bosutinib—MAP3K12—brain—intracranial aneurysm	0.00112	0.00241	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—intracranial aneurysm	0.00111	0.0024	CbGeAlD
Bosutinib—AXL—cerebellum—intracranial aneurysm	0.0011	0.00237	CbGeAlD
Bosutinib—MAP2K1—brain—intracranial aneurysm	0.00109	0.00236	CbGeAlD
Bosutinib—STK35—brain—intracranial aneurysm	0.00109	0.00236	CbGeAlD
Bosutinib—CSK—brain—intracranial aneurysm	0.00109	0.00235	CbGeAlD
Bosutinib—CSNK1A1—brain—intracranial aneurysm	0.00108	0.00233	CbGeAlD
Bosutinib—HCK—brain—intracranial aneurysm	0.00107	0.00232	CbGeAlD
Bosutinib—CLK1—brain—intracranial aneurysm	0.00107	0.00232	CbGeAlD
Bosutinib—ABL2—brain—intracranial aneurysm	0.00107	0.0023	CbGeAlD
Bosutinib—MAP2K5—midbrain—intracranial aneurysm	0.00106	0.00229	CbGeAlD
Bosutinib—SLK—cerebellum—intracranial aneurysm	0.00106	0.00228	CbGeAlD
Bosutinib—CAMK2G—brain—intracranial aneurysm	0.00105	0.00228	CbGeAlD
Bosutinib—BMP2K—brain—intracranial aneurysm	0.00105	0.00228	CbGeAlD
Bosutinib—EPHB4—cerebellum—intracranial aneurysm	0.00105	0.00227	CbGeAlD
Bosutinib—LRRK2—brain—intracranial aneurysm	0.00104	0.00226	CbGeAlD
Bosutinib—EGFR—brain—intracranial aneurysm	0.00104	0.00225	CbGeAlD
Bosutinib—CSF1R—midbrain—intracranial aneurysm	0.00103	0.00224	CbGeAlD
Bosutinib—FYN—cerebellum—intracranial aneurysm	0.00103	0.00222	CbGeAlD
Bosutinib—PTK2B—brain—intracranial aneurysm	0.00102	0.0022	CbGeAlD
Bosutinib—PDGFRB—medulla oblongata—intracranial aneurysm	0.001	0.00217	CbGeAlD
Bosutinib—MAP4K5—cerebellum—intracranial aneurysm	0.001	0.00217	CbGeAlD
Bosutinib—MAP3K3—cerebellum—intracranial aneurysm	0.001	0.00217	CbGeAlD
Bosutinib—CSNK1E—brain—intracranial aneurysm	0.001	0.00216	CbGeAlD
Bosutinib—SIK1—brain—intracranial aneurysm	0.000984	0.00213	CbGeAlD
Bosutinib—IRAK4—brain—intracranial aneurysm	0.000984	0.00213	CbGeAlD
Bosutinib—EPHA4—brain—intracranial aneurysm	0.000974	0.00211	CbGeAlD
Bosutinib—ERBB3—brain—intracranial aneurysm	0.000964	0.00209	CbGeAlD
Bosutinib—ULK3—brain—intracranial aneurysm	0.000962	0.00208	CbGeAlD
Bosutinib—MAP2K2—brain—intracranial aneurysm	0.000962	0.00208	CbGeAlD
Bosutinib—MAP3K2—brain—intracranial aneurysm	0.000955	0.00207	CbGeAlD
Bosutinib—MAP3K7—brain—intracranial aneurysm	0.000946	0.00205	CbGeAlD
Bosutinib—PTK2—brain—intracranial aneurysm	0.000936	0.00202	CbGeAlD
Bosutinib—TBK1—brain—intracranial aneurysm	0.000936	0.00202	CbGeAlD
Bosutinib—YES1—cerebellum—intracranial aneurysm	0.000926	0.002	CbGeAlD
Bosutinib—STK10—cerebellum—intracranial aneurysm	0.000918	0.00199	CbGeAlD
Bosutinib—PDGFRB—midbrain—intracranial aneurysm	0.000917	0.00198	CbGeAlD
Bosutinib—IRAK1—brain—intracranial aneurysm	0.000917	0.00198	CbGeAlD
Bosutinib—TAOK3—cerebellum—intracranial aneurysm	0.000915	0.00198	CbGeAlD
Bosutinib—RPS6KB1—brain—intracranial aneurysm	0.0009	0.00195	CbGeAlD
Bosutinib—ABL1—medulla oblongata—intracranial aneurysm	0.000895	0.00194	CbGeAlD
Bosutinib—FGR—brain—intracranial aneurysm	0.000894	0.00194	CbGeAlD
Bosutinib—SRC—cerebellum—intracranial aneurysm	0.000891	0.00193	CbGeAlD
Bosutinib—AXL—brain—intracranial aneurysm	0.000891	0.00193	CbGeAlD
Bosutinib—SLK—brain—intracranial aneurysm	0.000858	0.00186	CbGeAlD
Bosutinib—EPHB4—brain—intracranial aneurysm	0.000851	0.00184	CbGeAlD
Bosutinib—EPHA2—brain—intracranial aneurysm	0.000835	0.00181	CbGeAlD
Bosutinib—FYN—brain—intracranial aneurysm	0.000834	0.0018	CbGeAlD
Bosutinib—MAP2K5—cerebellum—intracranial aneurysm	0.00082	0.00177	CbGeAlD
Bosutinib—ABL1—midbrain—intracranial aneurysm	0.000818	0.00177	CbGeAlD
Bosutinib—MAP3K3—brain—intracranial aneurysm	0.000815	0.00176	CbGeAlD
Bosutinib—MAP4K5—brain—intracranial aneurysm	0.000815	0.00176	CbGeAlD
Bosutinib—CSF1R—cerebellum—intracranial aneurysm	0.0008	0.00173	CbGeAlD
Bosutinib—YES1—brain—intracranial aneurysm	0.000753	0.00163	CbGeAlD
Bosutinib—STK10—brain—intracranial aneurysm	0.000746	0.00161	CbGeAlD
Bosutinib—TAOK3—brain—intracranial aneurysm	0.000743	0.00161	CbGeAlD
Bosutinib—SRC—brain—intracranial aneurysm	0.000724	0.00157	CbGeAlD
Bosutinib—PDGFRB—cerebellum—intracranial aneurysm	0.00071	0.00154	CbGeAlD
Bosutinib—MAP2K5—brain—intracranial aneurysm	0.000666	0.00144	CbGeAlD
Bosutinib—CSF1R—brain—intracranial aneurysm	0.00065	0.00141	CbGeAlD
Bosutinib—ABL1—cerebellum—intracranial aneurysm	0.000632	0.00137	CbGeAlD
Bosutinib—PDGFRB—brain—intracranial aneurysm	0.000576	0.00125	CbGeAlD
Bosutinib—ABL1—brain—intracranial aneurysm	0.000514	0.00111	CbGeAlD
Bosutinib—ABCB1—medulla oblongata—intracranial aneurysm	0.000278	0.000602	CbGeAlD
Bosutinib—ABCB1—midbrain—intracranial aneurysm	0.000254	0.00055	CbGeAlD
Bosutinib—ABCB1—cerebellum—intracranial aneurysm	0.000197	0.000426	CbGeAlD
Bosutinib—ABCB1—brain—intracranial aneurysm	0.00016	0.000346	CbGeAlD
Bosutinib—STK4—Signaling Pathways—MMP9—intracranial aneurysm	0.000112	0.000209	CbGpPWpGaD
Bosutinib—MAP2K1—Axon guidance—MMP2—intracranial aneurysm	0.000112	0.000208	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—CCL2—intracranial aneurysm	0.000112	0.000208	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—MMP2—intracranial aneurysm	0.000111	0.000206	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—AGER—intracranial aneurysm	0.00011	0.000205	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—MMP2—intracranial aneurysm	0.000109	0.000203	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—AGER—intracranial aneurysm	0.000108	0.0002	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—AGER—intracranial aneurysm	0.000106	0.000198	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CTSS—intracranial aneurysm	0.000106	0.000198	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—NCF1—intracranial aneurysm	0.000106	0.000197	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—CCL2—intracranial aneurysm	0.000106	0.000197	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—AGER—intracranial aneurysm	0.000105	0.000196	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—CST3—intracranial aneurysm	0.000105	0.000196	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—AGER—intracranial aneurysm	0.000105	0.000195	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—AGER—intracranial aneurysm	0.000105	0.000195	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—NCF1—intracranial aneurysm	0.000105	0.000194	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—AGER—intracranial aneurysm	0.000104	0.000193	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—AGER—intracranial aneurysm	0.000103	0.000192	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—CST3—intracranial aneurysm	0.000103	0.000191	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000102	0.00019	CbGpPWpGaD
Bosutinib—BLK—Immune System—AGER—intracranial aneurysm	0.000102	0.00019	CbGpPWpGaD
Bosutinib—LCK—Immune System—CTSS—intracranial aneurysm	0.000102	0.00019	CbGpPWpGaD
Bosutinib—FGR—Immune System—AGER—intracranial aneurysm	0.000102	0.00019	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—NOS3—intracranial aneurysm	0.000102	0.000189	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—CCL2—intracranial aneurysm	0.000101	0.000188	CbGpPWpGaD
Bosutinib—ROCK1—Developmental Biology—MMP9—intracranial aneurysm	0.000101	0.000187	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NCF1—intracranial aneurysm	0.000101	0.000187	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—NOS3—intracranial aneurysm	0.0001	0.000187	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EDNRA—intracranial aneurysm	0.0001	0.000186	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—NOS3—intracranial aneurysm	9.96e-05	0.000185	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CTSB—intracranial aneurysm	9.96e-05	0.000185	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—NCF1—intracranial aneurysm	9.91e-05	0.000184	CbGpPWpGaD
Bosutinib—FYN—Disease—CST3—intracranial aneurysm	9.9e-05	0.000184	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EDNRA—intracranial aneurysm	9.87e-05	0.000184	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CST3—intracranial aneurysm	9.84e-05	0.000183	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CTSK—intracranial aneurysm	9.78e-05	0.000182	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CTSB—intracranial aneurysm	9.72e-05	0.000181	CbGpPWpGaD
Bosutinib—EGFR—Axon guidance—MMP2—intracranial aneurysm	9.71e-05	0.000181	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NCF1—intracranial aneurysm	9.7e-05	0.00018	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NCF1—intracranial aneurysm	9.7e-05	0.00018	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—CCL2—intracranial aneurysm	9.69e-05	0.00018	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—NCF1—intracranial aneurysm	9.67e-05	0.00018	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EDNRA—intracranial aneurysm	9.58e-05	0.000178	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—MMP9—intracranial aneurysm	9.54e-05	0.000177	CbGpPWpGaD
Bosutinib—LYN—Immune System—CTSB—intracranial aneurysm	9.52e-05	0.000177	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EDNRA—intracranial aneurysm	9.51e-05	0.000177	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CTSB—intracranial aneurysm	9.47e-05	0.000176	CbGpPWpGaD
Bosutinib—LYN—Immune System—NCF1—intracranial aneurysm	9.47e-05	0.000176	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—NOS3—intracranial aneurysm	9.45e-05	0.000176	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—SLC25A16—intracranial aneurysm	9.43e-05	0.000175	CbGpPWpGaD
Bosutinib—ABL1—Immune System—NCF1—intracranial aneurysm	9.42e-05	0.000175	CbGpPWpGaD
Bosutinib—LCK—Immune System—CTSK—intracranial aneurysm	9.42e-05	0.000175	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—AGER—intracranial aneurysm	9.39e-05	0.000175	CbGpPWpGaD
Bosutinib—FYN—Immune System—CTSB—intracranial aneurysm	9.37e-05	0.000174	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NCF1—intracranial aneurysm	9.35e-05	0.000174	CbGpPWpGaD
Bosutinib—FYN—Immune System—NCF1—intracranial aneurysm	9.32e-05	0.000173	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CTSB—intracranial aneurysm	9.32e-05	0.000173	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NCF1—intracranial aneurysm	9.27e-05	0.000172	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EDNRA—intracranial aneurysm	9.16e-05	0.00017	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EDNRA—intracranial aneurysm	9.16e-05	0.00017	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NCF1—intracranial aneurysm	9.15e-05	0.00017	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTSS—intracranial aneurysm	9.07e-05	0.000169	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—NOS3—intracranial aneurysm	9.01e-05	0.000168	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—NOS3—intracranial aneurysm	9e-05	0.000167	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—NOS3—intracranial aneurysm	9e-05	0.000167	CbGpPWpGaD
Bosutinib—MAP2K2—Axon guidance—MMP9—intracranial aneurysm	8.98e-05	0.000167	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—AGER—intracranial aneurysm	8.97e-05	0.000167	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NCF1—intracranial aneurysm	8.93e-05	0.000166	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EDNRA—intracranial aneurysm	8.83e-05	0.000164	CbGpPWpGaD
Bosutinib—CSK—Disease—NOS3—intracranial aneurysm	8.69e-05	0.000162	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—AGER—intracranial aneurysm	8.65e-05	0.000161	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—NOS3—intracranial aneurysm	8.64e-05	0.000161	CbGpPWpGaD
Bosutinib—FYN—Disease—NCF1—intracranial aneurysm	8.61e-05	0.00016	CbGpPWpGaD
Bosutinib—LYN—Axon guidance—MMP9—intracranial aneurysm	8.58e-05	0.00016	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NCF1—intracranial aneurysm	8.56e-05	0.000159	CbGpPWpGaD
Bosutinib—EGFR—Disease—CST3—intracranial aneurysm	8.55e-05	0.000159	CbGpPWpGaD
Bosutinib—ABL1—Axon guidance—MMP9—intracranial aneurysm	8.54e-05	0.000159	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—MMP2—intracranial aneurysm	8.53e-05	0.000159	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—CCL2—intracranial aneurysm	8.47e-05	0.000158	CbGpPWpGaD
Bosutinib—FYN—Axon guidance—MMP9—intracranial aneurysm	8.45e-05	0.000157	CbGpPWpGaD
Bosutinib—MAP2K1—Axon guidance—MMP9—intracranial aneurysm	8.41e-05	0.000156	CbGpPWpGaD
Bosutinib—PTK2—Immune System—AGER—intracranial aneurysm	8.36e-05	0.000155	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTSK—intracranial aneurysm	8.34e-05	0.000155	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—MMP9—intracranial aneurysm	8.33e-05	0.000155	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NCF1—intracranial aneurysm	8.33e-05	0.000155	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—EDNRA—intracranial aneurysm	8.32e-05	0.000155	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—MMP2—intracranial aneurysm	8.29e-05	0.000154	CbGpPWpGaD
Bosutinib—LCK—Disease—CST3—intracranial aneurysm	8.24e-05	0.000153	CbGpPWpGaD
Bosutinib—YES1—Immune System—AGER—intracranial aneurysm	8.24e-05	0.000153	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—MMP9—intracranial aneurysm	8.22e-05	0.000153	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NCF1—intracranial aneurysm	8.21e-05	0.000153	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—MMP2—intracranial aneurysm	8.15e-05	0.000152	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—MMP2—intracranial aneurysm	8.11e-05	0.000151	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CTSB—intracranial aneurysm	8.1e-05	0.000151	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NCF1—intracranial aneurysm	8.05e-05	0.00015	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—MMP2—intracranial aneurysm	8.02e-05	0.000149	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—MMP9—intracranial aneurysm	7.99e-05	0.000149	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—MMP2—intracranial aneurysm	7.98e-05	0.000148	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—CCL2—intracranial aneurysm	7.93e-05	0.000148	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EDNRA—intracranial aneurysm	7.86e-05	0.000146	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AGER—intracranial aneurysm	7.81e-05	0.000145	CbGpPWpGaD
Bosutinib—LCK—Immune System—CTSB—intracranial aneurysm	7.8e-05	0.000145	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NCF1—intracranial aneurysm	7.79e-05	0.000145	CbGpPWpGaD
Bosutinib—LCK—Immune System—NCF1—intracranial aneurysm	7.76e-05	0.000144	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EDNRA—intracranial aneurysm	7.75e-05	0.000144	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AGER—intracranial aneurysm	7.65e-05	0.000142	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—MMP9—intracranial aneurysm	7.58e-05	0.000141	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—NOS3—intracranial aneurysm	7.55e-05	0.00014	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—NOS3—intracranial aneurysm	7.49e-05	0.000139	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—NOS3—intracranial aneurysm	7.46e-05	0.000139	CbGpPWpGaD
Bosutinib—EGFR—Disease—NCF1—intracranial aneurysm	7.44e-05	0.000138	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—NOS3—intracranial aneurysm	7.37e-05	0.000137	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AGER—intracranial aneurysm	7.36e-05	0.000137	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EDNRA—intracranial aneurysm	7.35e-05	0.000137	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NCF1—intracranial aneurysm	7.33e-05	0.000136	CbGpPWpGaD
Bosutinib—EGFR—Axon guidance—MMP9—intracranial aneurysm	7.3e-05	0.000136	CbGpPWpGaD
Bosutinib—SRC—Disease—CST3—intracranial aneurysm	7.3e-05	0.000136	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—NOS3—intracranial aneurysm	7.27e-05	0.000135	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—MMP9—intracranial aneurysm	7.23e-05	0.000134	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—CCL2—intracranial aneurysm	7.2e-05	0.000134	CbGpPWpGaD
Bosutinib—LCK—Disease—NCF1—intracranial aneurysm	7.17e-05	0.000133	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—CCL2—intracranial aneurysm	7.07e-05	0.000131	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—CCL2—intracranial aneurysm	7.07e-05	0.000131	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—MMP2—intracranial aneurysm	6.93e-05	0.000129	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—MMP9—intracranial aneurysm	6.93e-05	0.000129	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EDNRA—intracranial aneurysm	6.92e-05	0.000129	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTSB—intracranial aneurysm	6.91e-05	0.000128	CbGpPWpGaD
Bosutinib—SRC—Immune System—NCF1—intracranial aneurysm	6.87e-05	0.000128	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—CCL2—intracranial aneurysm	6.83e-05	0.000127	CbGpPWpGaD
Bosutinib—HCK—Disease—NOS3—intracranial aneurysm	6.67e-05	0.000124	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AGER—intracranial aneurysm	6.43e-05	0.00012	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—NOS3—intracranial aneurysm	6.42e-05	0.000119	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—MMP9—intracranial aneurysm	6.41e-05	0.000119	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NCF1—intracranial aneurysm	6.41e-05	0.000119	CbGpPWpGaD
Bosutinib—SRC—Disease—NCF1—intracranial aneurysm	6.34e-05	0.000118	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—NOS3—intracranial aneurysm	6.3e-05	0.000117	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—NOS3—intracranial aneurysm	6.3e-05	0.000117	CbGpPWpGaD
Bosutinib—ERBB4—Disease—NOS3—intracranial aneurysm	6.28e-05	0.000117	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AGER—intracranial aneurysm	6.28e-05	0.000117	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NCF1—intracranial aneurysm	6.25e-05	0.000116	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ASAH1—intracranial aneurysm	6.25e-05	0.000116	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—MMP9—intracranial aneurysm	6.23e-05	0.000116	CbGpPWpGaD
Bosutinib—LYN—Immune System—AGER—intracranial aneurysm	6.14e-05	0.000114	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—NOS3—intracranial aneurysm	6.14e-05	0.000114	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—MMP9—intracranial aneurysm	6.13e-05	0.000114	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NCF1—intracranial aneurysm	6.12e-05	0.000114	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AGER—intracranial aneurysm	6.12e-05	0.000114	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—MMP9—intracranial aneurysm	6.1e-05	0.000113	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—NOS3—intracranial aneurysm	6.09e-05	0.000113	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—MMP9—intracranial aneurysm	6.06e-05	0.000113	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EDNRA—intracranial aneurysm	6.05e-05	0.000113	CbGpPWpGaD
Bosutinib—FYN—Immune System—AGER—intracranial aneurysm	6.05e-05	0.000112	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—MMP9—intracranial aneurysm	6.03e-05	0.000112	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NCF1—intracranial aneurysm	6.03e-05	0.000112	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AGER—intracranial aneurysm	6.02e-05	0.000112	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—MMP9—intracranial aneurysm	6e-05	0.000112	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NCF1—intracranial aneurysm	5.99e-05	0.000111	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MMP2—intracranial aneurysm	5.91e-05	0.00011	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EDNRA—intracranial aneurysm	5.91e-05	0.00011	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC25A16—intracranial aneurysm	5.81e-05	0.000108	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EDNRA—intracranial aneurysm	5.78e-05	0.000107	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—CCL2—intracranial aneurysm	5.71e-05	0.000106	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EDNRA—intracranial aneurysm	5.69e-05	0.000106	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EDNRA—intracranial aneurysm	5.66e-05	0.000105	CbGpPWpGaD
Bosutinib—ERBB3—Disease—NOS3—intracranial aneurysm	5.54e-05	0.000103	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—NOS3—intracranial aneurysm	5.43e-05	0.000101	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AGER—intracranial aneurysm	5.23e-05	9.72e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—MMP9—intracranial aneurysm	5.21e-05	9.69e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NCF1—intracranial aneurysm	5.21e-05	9.68e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—MMP9—intracranial aneurysm	5.15e-05	9.58e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—NOS3—intracranial aneurysm	5.09e-05	9.47e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—MMP9—intracranial aneurysm	5.06e-05	9.4e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—MMP9—intracranial aneurysm	5.06e-05	9.4e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—CCL2—intracranial aneurysm	5.05e-05	9.39e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—AGER—intracranial aneurysm	5.04e-05	9.36e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NCF1—intracranial aneurysm	5.02e-05	9.33e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—CCL2—intracranial aneurysm	4.94e-05	9.18e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EDNRA—intracranial aneurysm	4.92e-05	9.14e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—MMP9—intracranial aneurysm	4.88e-05	9.08e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—CCL2—intracranial aneurysm	4.87e-05	9.05e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EDNRA—intracranial aneurysm	4.74e-05	8.81e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—CCL2—intracranial aneurysm	4.72e-05	8.78e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—CCL2—intracranial aneurysm	4.69e-05	8.71e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CCL2—intracranial aneurysm	4.52e-05	8.4e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CCL2—intracranial aneurysm	4.52e-05	8.4e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—AGER—intracranial aneurysm	4.46e-05	8.29e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MMP9—intracranial aneurysm	4.45e-05	8.26e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NCF1—intracranial aneurysm	4.44e-05	8.26e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—NOS3—intracranial aneurysm	4.4e-05	8.18e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CCL2—intracranial aneurysm	4.35e-05	8.09e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—NOS3—intracranial aneurysm	4.34e-05	8.06e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EDNRA—intracranial aneurysm	4.2e-05	7.8e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NOS3—intracranial aneurysm	4.18e-05	7.77e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—CCL2—intracranial aneurysm	4.1e-05	7.63e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MMP9—intracranial aneurysm	4.08e-05	7.6e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NOS3—intracranial aneurysm	4.02e-05	7.48e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NOS3—intracranial aneurysm	4.02e-05	7.48e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NOS3—intracranial aneurysm	3.88e-05	7.21e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCL2—intracranial aneurysm	3.87e-05	7.2e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ASAH1—intracranial aneurysm	3.85e-05	7.16e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCL2—intracranial aneurysm	3.82e-05	7.1e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NOS3—intracranial aneurysm	3.8e-05	7.06e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NOS3—intracranial aneurysm	3.7e-05	6.89e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCL2—intracranial aneurysm	3.62e-05	6.74e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NOS3—intracranial aneurysm	3.57e-05	6.64e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NOS3—intracranial aneurysm	3.55e-05	6.6e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MMP9—intracranial aneurysm	3.53e-05	6.56e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MMP9—intracranial aneurysm	3.48e-05	6.47e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NOS3—intracranial aneurysm	3.45e-05	6.42e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCL2—intracranial aneurysm	3.41e-05	6.34e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NOS3—intracranial aneurysm	3.41e-05	6.33e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MMP9—intracranial aneurysm	3.35e-05	6.23e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NOS3—intracranial aneurysm	3.23e-05	6.01e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MMP9—intracranial aneurysm	3.23e-05	6e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MMP9—intracranial aneurysm	3.23e-05	6e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MMP9—intracranial aneurysm	3.11e-05	5.79e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NOS3—intracranial aneurysm	3.08e-05	5.73e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NOS3—intracranial aneurysm	3.04e-05	5.65e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCL2—intracranial aneurysm	2.98e-05	5.54e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NOS3—intracranial aneurysm	2.97e-05	5.53e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCL2—intracranial aneurysm	2.91e-05	5.41e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCL2—intracranial aneurysm	2.85e-05	5.3e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCL2—intracranial aneurysm	2.8e-05	5.21e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCL2—intracranial aneurysm	2.79e-05	5.19e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MMP9—intracranial aneurysm	2.77e-05	5.15e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP9—intracranial aneurysm	2.73e-05	5.08e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NOS3—intracranial aneurysm	2.66e-05	4.94e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS3—intracranial aneurysm	2.63e-05	4.89e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NOS3—intracranial aneurysm	2.59e-05	4.82e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP9—intracranial aneurysm	2.59e-05	4.82e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NOS3—intracranial aneurysm	2.54e-05	4.72e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NOS3—intracranial aneurysm	2.5e-05	4.65e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NOS3—intracranial aneurysm	2.49e-05	4.62e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—intracranial aneurysm	2.44e-05	4.54e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCL2—intracranial aneurysm	2.42e-05	4.51e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL2—intracranial aneurysm	2.34e-05	4.34e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—intracranial aneurysm	2.16e-05	4.02e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—intracranial aneurysm	2.13e-05	3.96e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—intracranial aneurysm	2.08e-05	3.87e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—intracranial aneurysm	2.08e-05	3.87e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—intracranial aneurysm	2.07e-05	3.84e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—intracranial aneurysm	2.04e-05	3.79e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—intracranial aneurysm	2.01e-05	3.73e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—intracranial aneurysm	1.99e-05	3.71e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—intracranial aneurysm	1.84e-05	3.43e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—intracranial aneurysm	1.73e-05	3.22e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—intracranial aneurysm	1.67e-05	3.1e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—intracranial aneurysm	1.48e-05	2.75e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—intracranial aneurysm	1.3e-05	2.42e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—intracranial aneurysm	8.03e-06	1.49e-05	CbGpPWpGaD
